Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Mar 20;8(1):30.
doi: 10.3390/antibiotics8010030.

A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Nicole Lounsbury  1 , Mary G Reeber  2 , Georges Mina  3 , Christiane Chbib  4
Affiliations
Review

A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections

Nicole Lounsbury et al. Antibiotics (Basel). .

Abstract

Objective: The objective of this review is to describe the outcomes of patients treated with ceftaroline in the non-Food and Drug Administration (FDA) approved indication of methicillin-resistant Staphylococcus aureus (MRSA) infections in both pediatric and adult populations.

Data sources: A systematic overview was conducted by searching PubMed, Medline, and The Cochrane Library up to January 2019.

Study selection and data extraction: All English-language clinical trials and case reports related to the efficacy of ceftaroline in new, not-yet-approved FDA indications in MRSA infections in pediatric or adult populations.

Data synthesis: In the case of MRSA bacteremia (MRSAB) infections, three different randomized studies in pediatric patients showed effectiveness of ceftaroline. When used in the case of adult populations with MRSA bacteremia, a small trial of 16 patients showed 50% clinical success in patients with acute bacterial skin and skin structure infections versus 63% clinical success in patients with community-acquired bacterial pneumonia. Another case series of six refractory case reports showed 50% clinical success of ceftaroline in patients with MRSA.

Conclusions: Although there are few case reports and limited data to date, ceftaroline fosamil should continue to be studied as an alternative therapy in MRSA infections in both pediatric and adult populations. Clinical success rates of ceftaroline were, in most cases, considered high when treating patients with MRSA infection. More clinical trials need to be studied. In the specific case of MRSA bacteremia, the treatment options remain few and ceftaroline should be extensively studied for the salvage treatment of MRSAB.

Keywords: MRSA bacteremia; bacteria infection; ceftaroline; cephalosporin; community-acquired infection; methicillin resistant Staphylococcus aureus (MRSA); pediatrics; pneumonia; safety; skin infection.

PubMed Disclaimer

Conflict of interest statement

No conflict of interest exists in this work; No competing interest declared.

Figures

Figure 1
Figure 1
Structure–activity relationships for active ceftaroline (R=H); the prodrug ceftaroline fosamil has the phosphono group at R = −P(=O)(OH)2 [11].
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Scott L.J. Ceftaroline fosamil: A review in complicated skin and soft tissue infections and community-acquired pneumonia. Drugs. 2016;76:1659–1674. doi: 10.1007/s40265-016-0654-4. - DOI - PubMed
    1. File T.M., Jr., Low D.E., Eckburg P.B., Talbot G.H., Friedland H.D., Lee J., Llorens L., Critchley I.A., Thye D.A., Focus 1 Investigators FOCUS1: A randomized, double blinded, multicenter, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftaroline in community-acquired pneumonia. J. Antimicrob. Chemother. 2011;66:19–32. doi: 10.1093/jac/dkr096. - DOI - PubMed
    1. Low D.E., File T.M., Jr., Eckburg P.B., Talbot G.H., Friedland H.D., Lee J., Llorens L., Crichley I.A., Thye D.A., Focus 2 Investigators FOCUS 2: A randomized, double blinded, multicenter, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J. Antimicrob. Chemother. 2011;66:33–44. doi: 10.1093/jac/dkr097. - DOI - PubMed
    1. File T.M., Jr., Wilcox M.H., Stein G.E. Summary of ceftaroline fosamil clinical trial studies and clinical safety. Clin. Infect. Dis. 2012;55:173–180. doi: 10.1093/cid/cis559. - DOI - PubMed
    1. Kollef M.H. New antimicrobial agents for methicillin-resistant Staphylococcus aureus. Crit. Care Resusc. 2009;11:282–286. - PubMed

LinkOut - more resources